Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $209.14 Average Price Target from Brokerages

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have earned a consensus rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $209.1429.

A number of research analysts have weighed in on PVLA shares. HC Wainwright reiterated a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Stephens reaffirmed an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This trade represents a 66.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new position in shares of Palvella Therapeutics during the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $35,000. Group One Trading LLC increased its position in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics during the 3rd quarter valued at approximately $36,000. Finally, Quantbot Technologies LP purchased a new position in Palvella Therapeutics during the second quarter valued at $71,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Trading Up 1.0%

Shares of PVLA opened at $156.55 on Friday. The firm’s 50-day moving average price is $137.17 and its 200-day moving average price is $121.91. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -32.41 and a beta of -0.17. Palvella Therapeutics has a 1-year low of $41.71 and a 1-year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, research analysts forecast that Palvella Therapeutics will post -6.36 EPS for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.